Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder.

ABSTRACT: Genetically informed drug development and repurposing is an attractive prospect for improving patient outcomes in psychiatry; however, the effectiveness of these endeavors is confounded by heterogeneity. We propose an approach that links interventions implicated by disorder-associated genetic risk, at the population level, to a framework that can target these compounds to individuals. Specifically, results from genome-wide association studies are integrated with expression data to prioritize individual "directional anchor" genes for which the predicted risk-increasing direction of expression could be counteracted by an existing drug. While these compounds represent plausible therapeutic candidates, they are not likely to be equally efficacious for all individuals. To account for this heter

SUBMITTER: Reay WR 

PROVIDER: S-EPMC9502060 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature